scholarly journals The role of imaging techniques in the diagnosis, staging and choice of therapeutic conduct in pregnancy associated breast cancer

2019 ◽  
Vol 21 (3) ◽  
pp. 336
Author(s):  
Iulian Goidescu ◽  
Georgiana Nemeti ◽  
Gabriela Caracostea ◽  
Dan Tudor Eniu ◽  
Angelica Chiorean ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Adverse Effects ◽  
Imaging Techniques ◽  
Diagnostic Techniques ◽  
Imaging Diagnosis ◽  
The Postponement ◽  
Therapeutic Possibilities ◽  
In Pregnancy

Breast cancer diagnosed during pregnancy is at increasing incidence due to the increased frequency of obesity, the postponement of the first pregnancy to later decades of life and the advances of diagnostic techniques. Clinical and imaging diagnosis is difficult during gestation due to adaptive changes of the maternal organism , the mammary glads in particular. Furthermore, the therapeutic approach is limited both by the possible side effects on the fetus and by the skepticism of the couple over these therapeutic regimens.The present paper aims to review the main diagnostic steps to confirm pregnancy associated breast cancer, as well as the therapeutic possibilities during this period, related to the potential adverse effects concerning pregnancy

Considerations on the Use of Aromatase Inhibitors in Postmenopausal Women With Breast Cancer

2020 ◽  
pp. 385-400
Author(s):  
Jeffrey D. Blaustein
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cognitive Function ◽  
Adverse Effects ◽  
Develop Breast Cancer ◽  
Laboratory Animals ◽  
Breast Cancers ◽  
The Brain

About 1 of every 8 women will develop breast cancer during her lifetime, and approximately 250,000 new cancer cases are expected annually as of 2017. Of those breast cancers, approximately 60% to 75% will express estrogen receptors, suggesting that estrogens are likely to promote growth of those tumors. Because the use of inhibitors of the synthesis of estrogens is the adjuvant treatment of choice for many women, it is essential that we understand the potential adverse effects on quality of life of those treatments. This review addresses the role of estrogens locally synthesized in the brain in laboratory animals and women, the effects of estrogens on cognitive function, the effects of synthesis blockers on cognitive function, and the limitations in performing experiments that will give us strong confidence in the results and conclusions.

Defining the role of glucocorticoids in inflammation

2018 ◽  
Vol 132 (14) ◽  
pp. 1529-1543 ◽  
Author(s):  
Simona Ronchetti ◽  
Graziella Migliorati ◽  
Stefano Bruscoli ◽  
Carlo Riccardi
Keyword(s):  
Clinical Practice ◽  
Side Effects ◽  
Adverse Effects ◽  
Molecular Mechanisms ◽  
Molecular Targets ◽  
Great Promise ◽  
Body Of Knowledge ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

An established body of knowledge and clinical practice has argued in favor of the use of glucocorticoids in various chronic inflammatory and autoimmune diseases. However, the very well-known adverse effects associated with their treatment hampers continuation of therapy with glucocorticoids. Analyses of the molecular mechanisms underlying the actions of glucocorticoids have led to the discovery of several mediators that add complexity and diversity to the puzzling world of these hormones and anti-inflammatory drugs. Such mediators hold great promise as alternative pharmacologic tools to be used as anti-inflammatory drugs with the same properties as glucocorticoids, but avoiding their metabolic side effects. This review summarizes findings about the molecular targets and mediators of glucocorticoid function.

The role of FDG PET/CT in patients with locoregional breast cancer recurrence: A comparison to conventional imaging techniques

2010 ◽  
Vol 36 (4) ◽  
pp. 387-392 ◽  
Author(s):  
T.S. Aukema ◽  
E.J.Th. Rutgers ◽  
W.V. Vogel ◽  
H.J. Teertstra ◽  
H.S. Oldenburg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Fdg Pet ◽  
Imaging Techniques ◽  
Cancer Recurrence ◽  
Breast Cancer Recurrence ◽  
Conventional Imaging ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals Current status and novel directions in triple negative breast cancer patients. Risk factors. Role of the platinum-based chemotherapy

2016 ◽  
Vol 11 (2) ◽  
pp. 122-126
Author(s):  
Olivia IONESCU ◽  
◽  
Irina BALESCU ◽  
Nicolae BACALBASA ◽  
◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Clinical Trials ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Controlled Vocabulary ◽  
Current Status ◽  
Platinum Based Chemotherapy ◽  
Therapeutic Possibilities

Rationale. Breast cancer (BC) has been recognized to be the most common type of cancer in women all over the world. One of the most aggressive subtype of BC is the triple negative breast cancer (TNBC) which is defined by the absence of estrogen receptor (ER) and progesterone receptor (PR) as well as the lack of overexpression of the human epidermal growth factor 2 (HER 2). Aim. As the estrogen and progesterone receptors as well as the expression of HER2 are lacking, a targeted therapy with anti-hormone agents and anti-HER2 cannot be utilized, the therapeutic possibilities for TNBC women are limited. The aim of this review is to present the current scientific data as well as the latest research in TNBC with focus on the risk factors as well as the current role of platinum-based chemotherapeutic agents and their future implications in TNBC treatment. Method. Information about the risk factors associated to TNBC as well as the chemotherapeutic regimens was searched through Pubmed and Medline using controlled vocabulary (e.g. breast cancer) and key words (e.g. neoadjuvant, triple negative, platinum). Systematic reviews, randomized and controlled clinical trials were analyzed. No restrictions regarding date or language were used. Conclusions. TNBC is a complex and heterogeneous disease, divided into many subtypes and with an aggressive evolution. Premenopausal women and African American women are far more likely to develop TNBC. More research is required in order to confirm the association between obesity, BMI, parity, use of oral contraceptives, alcohol and cigarette smoking and TNBC. Randomized clinical trials presented at the San Antonio Symposium suggest that platinum chemotherapy play an important role in the treatment of TNBC, especially early stage TNBC. Tumor-based measures of genomic instability will help to clarify the optimal use and activity of platinum in TNBC. However, it is clear than more epidemiological studies as well as the discovery of novel therapeutic possibilities are mandatory in order to unravel the complexity of this BC subtype, hence offering a chance to women diagnosed with TNBC.

Psilocybin-assisted therapy for depression: How do we advance the field?

2019 ◽  
Vol 54 (3) ◽  
pp. 225-231 ◽  
Author(s):  
Sally E Meikle ◽  
Paul Liknaitzky ◽  
Susan L Rossell ◽  
Margaret Ross ◽  
Nigel Strauss ◽  
...  
Keyword(s):  
Side Effects ◽  
Adverse Effects ◽  
Potential Role ◽  
Treatment Options ◽  
Clinical Environment ◽  
Psychedelic Drugs ◽  
Key Issues ◽  
New Treatment ◽  
Potential Use

In the quest for new treatment options for depression, attention is being paid to the potential role of psychedelic drugs. Psilocybin is of particular interest given its mechanism of action, its benefits in early trials and its relatively low side effects burden. This viewpoint outlines a number of key issues that remain to be elucidated about its potential use in the clinical environment, including clarification of the profile of people most likely to benefit and those who might experience adverse effects, longer-term outcomes and the role of psychotherapeutic input alongside the drug itself. There are also opportunities to understand better, the neurobiology underpinning its effects.

Predictors of patient-reported toxicities from endocrine therapy: Importance of illness perceptions, treatment beliefs, and fear of recurrence.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 542-542
Author(s):  
Xinni Song ◽  
Susan Faye Dent ◽  
Shailendra Verma ◽  
Mark J. Clemons ◽  
Nadine A. Graham ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Adverse Effects ◽  
Endocrine Therapy ◽  
Symptom Management ◽  
Self Report ◽  
Fear Of Cancer Recurrence ◽  
Management Interventions ◽  
Patient Reported ◽  
The Impact

542 Background: Numerous studies have documented the toxicities of endocrine therapy (ET) for early breast cancer (EBC) and their deleterious impact on quality of life and adherence. However, little is known about the factors that underlie patient's susceptibility to report toxicities. The identification of risk factors for toxicities from ET is important as it would allow early targeting of symptom management interventions for women more vulnerable to adverse effects of ET. This prospective study aims to examine the impact of pre-treatment perceptions of EBC, ET beliefs and fear of breast cancer (BC) recurrence (FBCR) on toxicities reported after 6 months of ET. Methods: Women diagnosed with EBC completed a survey prior to initiating endocrine therapy, then at 3, 6 and 12 months. Standardized self-report instruments were used to assess EBC perceptions, ET beliefs, FBCR and toxicities. Clinical and treatment variables were also evaluated. Univariate analyses and mulitivariate regression were conducted to identify factors associated (p<0.1) with side effects at 6 months. Results: Since 9/2010, 173 patients have consented and 84 (mean age = 60 y) have completed the questionnaires at baseline and after 6 months of ET. Controlling for age, none of the clinical or treatment variables (stage of disease, type of surgery, receipt of chemotherapy and radiation therapy) were significant univariate predictors of toxicities. In multiple regression, stronger perceptions that BC has serious consequences on their lives (β=0.218, p<0.05), greater concerns about the adverse effects of ET (β=0.215, p<0.05) and higher levels of FBCR (β=0.316, p<0.01) at baseline were associated with higher levels of reported toxicities. Conclusions: Baseline psychological factors predicted level of patient-reported toxicities to a larger extent than clinical/treatment factors. How patients perceived their illness, their beliefs about ET side effects and their fear of cancer recurrence are strongly associated with side effects experienced after 6 months of ET. These results could facilitate the identification of a subgroup of patients for early interventions to improve symptom management.

Role of Nutraceuticals in Cancer

2019 ◽  
pp. 388-406
Author(s):  
Kiran Dahiya ◽  
Rakesh Dhankhar
Keyword(s):  
Side Effects ◽  
Adverse Effects ◽  
Mechanism Of Action ◽  
Healthcare Professionals ◽  
Standard Treatment ◽  
Treatment Modalities ◽  
Active Components ◽  
Prevention And Treatment ◽  
Prevention Of Cancer

Nutraceuticals are increasingly becoming popular for prevention and treatment of cancer. Association of adverse effects with standard treatment modalities of cancer has led to consideration of safer approaches. Nutraceuticals may help in prevention of cancer as well as in treatment and avoidance of side effects associated with chemo-radiation. The active components of nutraceuticals are known as phytochemicals. Many mechanisms have been put forward for the actions of these phytochemicals but an exact mechanism for a well defined role of a particular phytochemical in a specific type of cancer is yet to be elucidated. Thus, nutraceutical industry has emerged as a research oriented sector. It is important for the healthcare professionals to understand the categories, research developments, mechanism of action and areas of concern in the field of nutraceuticals.

Sign in / Sign up

Export Citation Format

Share Document